Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Journal of molecular biology - 4 May 2007

Wu Herren, Pfarr David S, Johnson Syd, Brewah Yambasu A, Woods Robert M, Patel Nita K, White Wendy I, Young James F, Kiener Peter A

Abstract excerpt

Respiratory syncytial virus (RSV) is the leading cause of viral bronchiolitis and pneumonia in infants and children. Currently, palivizumab is the only approved monoclonal antibody (mAb) for prophylaxis of RSV. However, a small percentage of patients are not protected by palivizumab; in addition, palivizumab does not inhibit RSV replication effectively in the upper respiratory tract. We report here the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross Reactions
Share to Macaca fascicularis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neutralization Tests

Share to Pan troglodytes

Share to Respiratory Syncytial Virus Infections

Share to Respiratory Syncytial Viruses

Share to Respiratory System

Share to Sigmodontinae

Source

Identifiers

PMID: 17362988
DOI: 10.1016/j.jmb.2007.02.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.PMID 17362988Read ↗

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.Semantic proximity Read ↗

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.Semantic proximity Read ↗

Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia.Semantic proximity Read ↗

The long road to protect infants against severe RSV lower respiratory tract illnessSemantic proximity Read ↗

Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion proteinSemantic proximity Read ↗

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.Semantic proximity Read ↗

Rational antigen engineering and mucosal delivery design for next-generation RSV vaccinesSemantic proximity Read ↗

Molecular modeling predicts novel antibody escape mutations in respiratory syncytial virus fusion glycoproteinSemantic proximity Read ↗

Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.Semantic proximity Read ↗

Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein.Semantic proximity Read ↗

A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton RatsSemantic proximity Read ↗

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.